About Oxeia Biopharmaceuticals
Oxeia Biopharmaceuticals is a company based in San Diego (United States) founded in 2014. Oxeia Biopharmaceuticals has raised $310 thousand across 1 funding round. Oxeia Biopharmaceuticals offers products and services including Concussion Therapeutics. Oxeia Biopharmaceuticals operates in a competitive market with competitors including Tonix Pharma, Edge Therapeutics, veriNOS pharmaceuticals, Neuraptive and Ischemix, among others.
- Headquarter San Diego, United States
- SectorsHealthcare
- Email••••••••
- Website oxeiabiopharma.com
- Social X
- Legal Name Oxeia Biopharmaceuticals, Inc.
- Total Equity Funding$310K (USD)
in 1 rounds
- Latest Funding Round$310K (USD), Seed
Jun 2014
Products & Services of Oxeia Biopharmaceuticals
Oxeia Biopharmaceuticals offers a comprehensive portfolio of products and services, including Concussion Therapeutics.
Develops treatments to address concussion symptoms and recovery.
Funding Insights of Oxeia Biopharmaceuticals
Oxeia Biopharmaceuticals has successfully raised a total of $310K through 1 strategic funding round. The most recent funding activity was a Seed round of $310 thousand completed in June 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $310,000
- Total Rounds 1
- Last Round Seed — $310,000
- First Round $310,000
(Jun 2014)
All 1 funding rounds of Oxeia Biopharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2014 | $310,000 | Seed | – | – | – |
People of Oxeia Biopharmaceuticals
15 people are tracked at Oxeia Biopharmaceuticals (1 in leadership, 13 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Michael Wyand | CEO & Director | Leadership |
Kartik Shah | Director & Co-founder | Board & advisors |
Murray B Stein | Advisor | Board & advisors |
Ross D. Zafonte | Advisor | Board & advisors |
Mark Iwicki | Director | Board & advisors |
Chris Nowinski | Advisor | Board & advisors |
Mark H. Corrigan | Advisor | Board & advisors |
Gerald Grant | Advisor | Board & advisors |
Anjan Chatterji | Advisor | Board & advisors |
Richard Sherman | Advisor | Board & advisors |
Isaiah Kacyvenski | Advisor | Board & advisors |
Darius Naigamwalla | Advisor | Board & advisors |
Ted Raad | Director | Board & advisors |
Alex Smith | Director | Board & advisors |
Holly P. | Operations Manager | Team |
Complete people profiles for Oxeia Biopharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Oxeia Biopharmaceuticals
2 dated milestones of Oxeia Biopharmaceuticals, from founding to its latest funding, stage changes and deals.
- Founded Oxeia Biopharmaceuticals is founded.
- Funding First funding round of $310K.
Competitors of Oxeia Biopharmaceuticals
Oxeia Biopharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tonix Pharma, Edge Therapeutics, veriNOS pharmaceuticals, Neuraptive and Ischemix, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tonixpharma.com | 2007 | New York, United States | $4.45M | 117 | Next-generation medicines for CNS and immunological disorders are developed. | |
| edgetherapeutics.com | 2009 | New Providence, United States | $164.73M | 26 | Novel therapies for acute neurological conditions are developed and commercialized. | |
| verinos-pharma.com | 1998 | Wurzburg, Germany | $62.7M | – | Developer of therapeutics for retina and brain diseases | |
| neuraptive.com | 2016 | Lafayette, United States | $12.5M | – | Therapeutic solution for the repair of cut and crushed peripheral nerves. | |
| ischemix.com | 2006 | Grafton, United States | $6.6M | – | Developer of cytoprotective therapy for traumatic brain injury | |
| proniras.com | 2018 | Seattle, United States | $11.23M | 2 | Small molecules are developed for seizures and brain injury treatment. | |
| renetx.com | 2010 | New Haven, United States | $13.42M | – | First-in-class therapeutics for CNS injuries are developed by the company. | |
| freeoxbiotech.com | 2017 | Barcelona, Spain | $572,841 | – | Therapies for ischaemic stroke treatment are being developed. | |
| neurexistherapeutics.com | 2020 | Aurora, United States | $605,000 | – | Neuroprotective therapeutic peptides are developed for brain disorder treatment. |
Detailed competitors of Oxeia Biopharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Oxeia Biopharmaceuticals
The website of Oxeia Biopharmaceuticals (oxeiabiopharma.com) receives about 3.3K visits a month.
- Monthly visits3.3K
▲ 11.8% vs previous month
Websites whose visitors overlap most with Oxeia Biopharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| prometrika.com | 100% | – | #2,751,954 | View details | |
| cugene.com | 99% | 1.1K | #13,064,449 | View details | |
| vedantabio.com | 97% | 5.6K | #3,168,764 | View details | |
| hcbioscience.com | 97% | – | – | View details | |
| nchromabio.com | 96% | 3.3K | #5,351,318 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Oxeia Biopharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Oxeia Biopharmaceuticals
Complete news archive for Oxeia Biopharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Oxeia Biopharmaceuticals
10 companies that operate in the same segment as Oxeia Biopharmaceuticals (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Oxeia Biopharmaceuticals
Oxeia Biopharmaceuticals was founded in 2014.
Oxeia Biopharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Oxeia Biopharmaceuticals is a funded company, having raised a total of $310K across 1 funding round to date. The company's 1st funding round was a Seed of $310K, raised on Jun 2014.
Oxeia Biopharmaceuticals is a clinical stage biotech company developing drug treatments for concussion and underlying neuro-metabolic dysfunction. The company believes that Concussions and neurodegeneration share common molecular pathology including acute neuro-mitochondrial dysfunction. Oxeias lead program, OXE-103, is a mitochondrial stabilizer that crosses the blood brain barrier and activates a well-characterized pathway that directly promotes normal mitochondrial activity. In doing so brain energy homeostasis is restored. OXE-103 was identified as a therapeutic candidate for concussion through research on the neuro-enteric axis and its affect on brain physiology. Pre-clinical research with OXE-103 in traumatic brain injury models is claimed to have demonstrated efficacy and confirmed mechanism of activity. Oxeia is now working with its advisors to plan human clinical studies for the molecule.
Oxeia Biopharmaceuticals's top competitors include Tonix Pharma, Neuraptive and Neurexis Therapeutics.
Oxeia Biopharmaceuticals offers Concussion Therapeutics.
Oxeia Biopharmaceuticals operates through Oxeia Biopharmaceuticals, Inc..